Chronic Obstructive Pulmonary Disease (COPD) Drugs Market

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market is valued at USD 10.41 Billion in 2021 and expected to reach USD 13.70 Billion by 2028 with a CAGR of 3.5% over the forecast period.

Increasing Geriatric Population and Increasing Prevalence of Chronic Obstructive Pulmonary Disease (COPD) globally are anticipated to drive growth of Global Chronic Obstructive pulmonary Disease (COPD) Drugs Market.

Market Analysis of Chronic Obstructive Pulmonary Disease (COPD) Drugs-

Chronic obstructive pulmonary disease (COPD), is a group of progressive lung diseases. It is a chronic inflammatory lung disease which causes obstructed airflow from the lungs. Its major symptoms are; breathing difficulty, cough, mucus (sputum) production and wheezing. It is caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. It usually takes a long time to develop. In the developing countries, it often occurs in people exposed to fumes from burning fuel for cooking and heating in poorly ventilated homes. In developed countries, the main cause of chronic obstructive pulmonary disease is tobacco smoking. About 90 percent of people who have COPD are smokers or former smokers. Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market is expected to witness a significant growth owing to the increasing prevalence of COPD worldwide.

Global chronic obstructive pulmonary disease (COPD) drugs market report is segmented on the basis of product type, application and region & country level. Based upon product type, global chronic obstructive pulmonary disease (COPD) drugs market is classified into bronchodilators, glucocorticoids and others. Based upon application, global chronic obstructive pulmonary disease (COPD) drugs market is divided into prevention, diagnostic and treatment.

The regions covered in this Chronic Obstructive pulmonary Disease (COPD) Drugs Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of Chronic Obstructive pulmonary Disease (COPD) Drugs is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Key Players-

Some major key players for global chronic obstructive pulmonary disease (COPD) drugs market are -

• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Circassia Pharmaceuticals
• GlaxoSmithKline
• Merck & Co.
• Mundipharma
• Mylan N.V. (now part of Viatris Inc.)
• Novartis
• Roche
• Sunovion Pharmaceuticals
• Teva Pharmaceutical Industries
• Theravance Biopharma
• Vectura Group
• Others

Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Segmentation-

By Drug Class Type

• Bronchodilators
• Inhaled Corticosteroids
• Combination Therapy

By Route of Administration

• Inhalation
• Oral
• Injectable

By Disease Severity

• Mild to Moderate COPD
• Severe COPD
• Very Severe COPD

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Regional & Country Analysis:

• North America

• U.S.
• Mexico
• Canada

• Europe

• UK
• France
• Germany
• Italy

• The Asia Pacific

• China
• Japan
• India
• Southeast Asia

• South America

• Brazil,
• Argentina
• Columbia

• The Middle East and Africa

• GCC
• Africa
• Rest of the Middle East and Africa

Increasing Geriatric Population and Increasing Prevalence of Chronic Obstructive Pulmonary Disease (COPD) Drives the Growth of Global Chronic Obstructive pulmonary Disease (COPD) Drugs Market

The major factor driving the growth of global chronic obstructive pulmonary disease (COPD) drugs market is the increasing prevalence increase in prevalence of chronic obstructive pulmonary disease globally which is expected to foster the demand for chronic obstructive pulmonary disease (COPD) drugs. For example; AS per WHO; The Global Burden of Disease Study reports a prevalence of 251 million cases of COPD globally in 2016. It is estimated that COPD will become the third leading cause of death worldwide by 2030. The primary cause of COPD is exposure to tobacco smoke (either active smoking or second­hand smoke). Increasing Tobacco consumption is one of the primary cause of COPD. Thus increasing Tobacco consumption is also expected to drive the market growth. COPD is likely to increase in coming years due to higher smoking prevalence and aging populations in many countries. Some cases of COPD are due to long-term asthma. For example; Asthma affects an estimated 300 million individuals worldwide. Annually, the World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide.

In addition, increasing geriatric population and growing consumer awareness about the latest and advanced treatment options are also supplementing the market growth. Furthermore, increasing healthcare spending and improving healthcare infrastructure with the favorable government initiatives are also driving the market growth. Moreover, increasing research and development in this field to develop more advanced treatment options of COPD can provide various opportunities for the further growth of the market.

North America is Expected to Witness a Significant Growth in the Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.

The Global Chronic Obstructive pulmonary Disease (COPD) Drugs Market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to capture significant share of the global chronic obstructive pulmonary disease (COPD) drugs market within the forecast period attributed to the highly developed healthcare infrastructure and increasing cases of chronic obstructive pulmonary disease (COPD) drugs in this region. For example; COPD is a leading cause of death in the United States, affecting 16 million Americans. Both emphysema and chronic bronchitis are the two most common types of COPD. In 2016, more than 8.9 million Americans Trusted Source were diagnosed with chronic bronchitis and nearly 75 percent of cases involved people over the age of 45.

Europe is projected to capture the second largest share of global chronic obstructive pulmonary disease (COPD) drugs market owing to the increasing geriatric population in this region. Asia Pacific is anticipated to witness a fastest growth with a high CAGR in global chronic obstructive pulmonary disease (COPD) drugs market owing to the increasing incidence of respiratory diseases in this region.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 10.41 Billion
Base year considered	2020
Forecast Period CAGR %:	3.5%
Market Size Expected in 2028:	USD 13.70 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, Circassia Pharmaceuticals, GlaxoSmithKline, Merck & Co., Mundipharma, Mylan N.V. (now part of Viatris Inc.), Novartis, Roche, Sunovion Pharmaceuticals, Teva Pharmaceutical Industries, Theravance Biopharma, Vectura Group, Others.
Segments Covered	By Product Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa